Assessing Mesoblast’s Valuation After Recent Share Price Weakness And Conflicting Growth Signals

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.

Mesoblast share move and recent return profile

Mesoblast (ASX:MSB) recently closed at A$2.15, catching attention after a mixed set of short and longer term returns, including a 0.5% gain over the past day and a 6.5% decline over the past week.

See our latest analysis for Mesoblast.

While the 1 day share price return was slightly positive, the 7 day and year to date share price returns have been weak. However, the 1 year and 3 year total shareholder returns remain firmly positive, suggesting earlier optimism is being reassessed.

If Mesoblast has you thinking about where else growth stories might emerge in healthcare, this could be a useful moment to scan 10 healthcare AI stocks

With Mesoblast trading at A$2.15 alongside an indicated intrinsic discount and a sizeable gap to analyst targets, the key question is simple: is there real value still on the table, or is the market already pricing in future growth?

Most Popular Narrative: 43.9% Undervalued

Mesoblast's most followed narrative points to a fair value of A$3.83 per share, compared with the latest close at A$2.15, putting a spotlight on what is built into those assumptions.

The heart failure program for rexlemestrocel L, with RMAT designation and FDA feedback that existing trial data could support an accelerated approval filing alongside a planned confirmatory study, gives Mesoblast a potential entry into a very large cardiovascular market. Outcomes would primarily influence long term revenue scale and the path to sustainable earnings.

Read the complete narrative.

Curious what kind of revenue curve and margin profile would need to sit behind that story for the numbers to line up? The narrative leans on sharp top line expansion, a swing from losses to meaningful profitability, and a future earnings multiple that usually goes to companies seen as clear winners. The exact mix of growth, margin uplift and valuation is where the real tension sits.

Result: Fair Value of A$3.83 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the story could change quickly if Ryoncil sales stay well below US$50 million in cash spend or if key late stage trials encounter regulatory or timing setbacks.

Find out about the key risks to this Mesoblast narrative.

Another view on what the market is paying for growth

While the SWS DCF model points to Mesoblast trading below its estimated future cash flow value at A$3.05 per share, simple price based checks tell a different story, with a P/S of 30.5x versus a fair ratio of 5.7x and 16.8x for the Australian Biotechs industry. Is the market overpaying for growth, or is the DCF putting too much weight on long range assumptions?

Story Continues

See what the numbers say about this price — find out in our valuation breakdown.ASX:MSB P/S Ratio as at Apr 2026

Next Steps

The mix of optimism and questions around Mesoblast is clear. This is a good time to review the data first hand and shape your own stance. To see what supporters are focusing on, take a closer look at the 3 key rewards

Looking for more investment ideas?

If Mesoblast has sharpened your focus, this is the moment to widen your search and compare it with other clear, data driven opportunities on the platform.

Spot potential value opportunities early by scanning the 9 high quality undervalued stocks that combine quality fundamentals with appealing pricing signals. Prioritise resilience and sleep easier at night by checking the 8 resilient stocks with low risk scores that score well on financial strength and risk metrics. Get ahead of the crowd by reviewing the screener containing 14 high quality undiscovered gems that pair solid fundamentals with relatively low market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include MSB.AX.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments